Renin-Angiotensin-Aldosterone System (RAAS) Blockers

Created

2021-03-01

Last Modified

Files

1 Download↓
rx_2021_03_ReninAngioTensinAldosteronSystemBlockers_V2.csv (139.38 KB)
↓

Tags













Abstract

This broad concept set was intended to identify patients who received angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and other agents acting on the renin-angiotensin system.

Affiliation(s)

Children's Hospital of Philadelphia

Funder(s)

Provenance

Treatment of Henoch-Schonlein purpura (HSP) Nephritis

Description

This concept set identifies renin-angiotensin-aldosterone system-blocking medications including angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and other agents acting on the renin-angiotensin system.

This medication concept set includes the following ingredients: aliskiren, azilsartan, benazepril, candesartan, captopril, cilazapril, enalapril, eprosartan, fosinopril, imidapril, irbesartan, lisinopril, losartan, moexipril, olmesartan, perindopril, quinapril, ramipril, spirapril, telmisartan, trandolapril, valsartan, and zofenopril. It also includes combinations of these ingredients with other antihypertensive medications. This code list was generated by taking the descendants of all the ACE, ARB, and other RAAS agent ingredients of interest, and string matching on the concept_name of the ingredient.

Technical Note: This concept set was created when ingredients were required for some sites. It could be enhanced by using SCDF drug levels and taking descendants, making this easier to refresh.

This concept set is identical to its predecessor, but it has been expanded to include RxNorm Extension codes in addition to RxNorm codes.

Development Code

Vocabulary

RxNorm , RxNorm Extension

Clinical Subjects Headings

Vasoconstrictor
Cardiovascular Agent

Related Resource

Related Phenotype

Related Person

Related Study

Thumbnail Image
Treatment of Henoch-Schonlein purpura (HSP) Nephritis
Cincinnati Children's Hospital Medical Center
Study to evaluate clinical and laboratory factors at initial presentation which can predict the course of patients with Henoch-Schonlein Purpura (HSP) nephritis, including duration of proteinuria and development of chronic kidney disease/end-stage renal disease, and to evaluate the association of various treatment regimens with outcomes such as time to remission of proteinuria and change in glomerular filtration rate in children with HSP nephritis.

Related Concept Set

Related Publications

Stone HK, Mitsnefes M, Dickinson K, et al. 2023. “Clinical course and management of children with IgA vasculitis with nephritis.” Pediatr Nephrol 38, 3721�3733.
DOI: 10.1007/s00467-023-06023-8

Creative Commons license

a CC-BY Attribution 4.0 License.
Except where otherwised noted, this item's license is described as a CC-BY Attribution 4.0 License.

Version History

Now showing 1 - 2 of 2
VersionDateSummary
2*
 2024-09-26 09:56:15
Modified to include RXNorm Extension codes.
1
 2024-06-10 15:03:14
* Selected version